AACR Annual Meeting

Soricimed Biopharma Inc. ("Soricimed"), a clinical-stage pharmaceutical company discovering and developing peptide-based cancer therapeutics, is pleased to announce two poster presentations at the American Association of Cancer Research (AACR) annual meeting, taking place in Chicago, IL April 14-18th, 2018. The presentations are based on pre-clinical and clinical research conducted on the company’s lead anti-cancer drug candidate SOR-C13, a first-in-class inhibitor of the TRPV6 calcium channel.

Abstract Title: The central role of NFAT signalling in the mechanism of action of the TRPV6 oncochannel inhibitor and clinical candidate SOR-C13

Session Category: Experimental and Molecular Therapeutics

Session Title: New Targets 1

Session Date and Time: Monday Apr 16, 2018 8:00AM - 12:00PM

Location: McCormick Place South, Exhibit Hall A, Poster Section 40

Poster Board Number: 11

Permanent Abstract Number: 1936 

Abstract Title: Molecular profiling of hormone-resistant prostate cancer cells with TRPV6 oncochannel knockout/knockdown

Session Category: Experimental and Molecular Therapeutics

Session Title: New Targets 2

Session Date and Time: Monday Apr 16, 2018 1:00PM - 5:00PM

Location: McCormick Place South, Exhibit Hall A, Poster Section 40

Poster Board Number: 1

Permanent Abstract Number: 2891

For more information about the American Assosciation for Cancer Research please visit: www.aacr.org

Sign up to receive updates from Soricimed

Powered by Innovasium